InFlectis BioScience Announces Successful Completion of Phase 1 Clinical Trial of Oral IFB-088 (Press Release).
InFlectis BioScience SAS announces favorable results from the Single Ascending Dose (SAD) part of the Phase 1 trial (study P-188) that evaluated IFB-088 administered by oral route in healthy volunteers (Press Release).
Chen Y. et al, (2019). Sephin 1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis. Brain doi:10.1093/brain/awy322
InFlectis BioScience SAS announces that the French National Agency for Medicines and Health Products Safety (ANSM) approved the Company’s Clinical Trial Application (CTA) to begin a Phase 1 study of IFB-088 (study P-188) in healthy volunteers. (Press Release).
InFlectis BioScience SAS strengthens its intellectual property position with the issuance of patents covering the use of its drug candidate IFB-088 to treat Charcot-Marie-Tooth (CMT) disease in the EU and the USA (Press Release).
InFlectis BioScience announced the completion of a Series A financing round amounting to €6 million to accelerate the clinical development of its drug candidate IFB-088 (Press Release). The financing was co-led by CM-CIC INNOVATION and REMIGES VENTURES with the participation of its historic shareholders, GO CAPITAL and PARTICIPATIONS BESANÇON.
InFlectis BioScience is pleased to announce today that European Commission has granted orphan drug designation to its drug candidate IFB-088 for the treatment of Charcot-Marie-Tooth disease (Press Release).
InFlectis BioScience is pleased to announce today that the US FDA has granted orphan drug designation to its drug candidate IFB-088 for the treatment of Charcot-Marie-Tooth disease (Press Release).